Kairos Pharma, Ltd. (KAPA)

• Market cap: $25.5M
• 1 day: 4.24%
• 5 days: 6.96%
• 1 month: 32.26%
• 3 months: 92.49%
• 6 months: 7.89%
• Year to date: -19.61%
• 1 year: -52.69%
• 5 years: -52.69%
• 10 years: -52.69%
• Sector: Healthcare
• Industry: Drug Manufacturers - General

About: Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. It is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma.

Employees: 4

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

67% more first-time investments, than exits

New positions opened: 5 | Existing positions closed: 3

13% more funds holding

Funds holding: 8 [Q1] → 9 (+1) [Q2]

10.48% less ownership

Funds ownership: 11.51% [Q1] → 1.04% (-10.48%) [Q2]

92% less capital invested

Capital invested by funds: $1.46M [Q1] → $123K (-$1.34M) [Q2]

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $9 632% upside
• Avg. target: $9 632% upside
• High target: $9 632% upside

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

D. Boral Capital Jason Kolbert

632% upside $9

Buy Maintained

16 Jul 2025